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1. Introduction 
Neuroenhancement will become an important topic of medical ethics in future years and 
decades, due to the increasing insights of neuroscience into the functions of the brain and 
the growing possibilities of meaningful interventions. Consequently, several crucial topics 
need to be discussed in order to address this emerging issue, and these topics correspond to 
the following sections of this article: 
1. Introduction 
2. Enhancement: How is enhancement defined? Which topics in the theory of medicine 
does it touch on, and which concepts help to understand it better? 
3. Neuroenhancement and its categories: What is neuroenhancement in particular? What 
are the ends and methods of neuroenhancement? Which subtypes exist, and how can 
they be classified? 
4. Pharmacological and technological neuroenhancement: Which medication is used for 
pharmacological neuroenhancement? How may technological advancements be utilized 
to achieve neuroenhancement? 
5. Principles in medical ethics: How are ethical judgments usually made in medical ethics? 
According to which criteria should neuroenhancement be assessed in general? 
6. Ethical assessment of neuroenhancement: Which arguments are used to support or 
criticize neuroenhancement? What are the advantages and disadvantages? How can 
neuroenhancement currently be assessed and judged? 
7. Conclusion 
2. Enhancement 
Enhancement strategies in medicine, in general, are opposed to the classic framework of 
medical interventions – namely therapeutic, preventive, rehabilitative, and palliative 
measures –, in so far as no medical reasons, i.e. indications, for them exist: The people who 
request enhancements are not affected by disease according to classic standards and have 
not received a medical diagnosis related to their wishes. The intention behind enhancements 
is the improvement of subjective well-being and a higher quality of life. Although a general 
definition differentiates between therapy and enhancement, the dividing line needs to be 
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outlined separately for each type of treatment. A “treatment” for enhancement purposes is 
not synonymous with “therapy” any longer. Examples for enhancement include aesthetic 
surgery, doping in sports, and the use of presumed anti-aging medication. 
 
Fig. 1. Medicine comprises a multitude of different concepts for the wide notion of health 
care. Enhancement, however, is not usually considered a classic part of this, even though 
overlaps exist in expertise and methods. 
The “enhancement” concept elicits a number of questions in the realm of the theory of 
medicine (Groß, 2011): What is a “disease” state, as opposed to “health”? Can a state of 
“normalcy” be defined? Are these views not culture-sensitive and changing throughout 
history? In addition, social and ethical concerns follow: In which way is the physician-
patient relationship going to change when more enhancement options become available? Is 
the “patient” concept in medicine replaced by a “client” concept? 
 
Fig. 2. The difference between medicine and enhancement may, in simplified form, be 
portrayed by antonyms, although the conceptual distinction is complex and possesses many 
implications, which still need to be pondered in the theory of medicine. 
Distinguishing between therapy and enhancement is culture-dependent. The differences 
between them cannot be determined by science alone. Rather, it is the role of science to 
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provide data about biological and medical facts. Based on this, societies then decide which 
functional states count as “normal”, “variant”, “different”, or “diseased”, just to name a few 
possibilities for overall assessments. These judgments are difficult to make, given the 
complexities that result from an interaction between phenotypical features that are 
problematic to classify individually themselves. Three specific examples deserve mention: 
complications of features, population biology, and life stages. 
Complications of features: A population may possess a feature M in the majority of cases, with 
a complication rate of X% for a serious health problem, which is undesirable according to 
public opinion. In addition, there may be a variant feature V in a minority, with a higher 
complication rate of (X+Y)% for the serious complication. How is social acceptance for 
feature V achieved on the individual or the population level? When does feature V become a 
disease? Does this depend on the percentage with which it occurs in the population, on the 
seriousness of the complication, or on the complication rate? These questions cannot be 
contemplated within science alone; the answers require a qualified insight into the practices, 
needs, and desires of a culture. 
Population biology: From a population standpoint, e.g. in evolution, it is advantageous to 
produce a variability of features, within certain limits. This makes the population more 
stable in its niche. The features that are currently present have developed over many 
generations and are balanced with each other. Under these circumstances, simultaneous, 
congruent shifts in features can reduce adaptive capacities and may be detrimental for a 
population as a whole, although they could certainly be beneficial at times as well. When are 
such feature shifts healthy or abnormal? – In parallel, it is unclear what the sequelae will be 
when a significant number of humans want to change their appearances, skills, or habits in a 
certain direction at the same time through enhancement. From a societal perspective, it may 
be better to discourage such a desire. 
Life stages: It remains unclear how to classify changes that occur relatively often during 
temporary stages of life only, for example childhood and puberty, pregnancy and old age. Is 
lower extremity edema during pregnancy normal or a disease? Is cognitive decline with 
increasing age normal, or is old age a disease with dementia as one of its signs? These 
puzzles illustrate that the dividing line between health and disease becomes blurry in 
special, but still fairly common situations. Sometimes, it is best to explain states in terms of 
their physiology and pathophysiology rather than to apply a biased term too early. 
In summary, the concept of enhancement is vague because the notion of disease in medicine 
is debated as well. In addition, the intentions for enhancements are subjective: What counts 
as an improvement for one person may be unacceptable for another. 
3. Neuroenhancement and its categories 
Neuroenhancement is the use of enhancement strategies – according to the definition for 
enhancement in general – that affect the nervous system. More specifically, such a use, in the 
narrow sense, mostly concerns the central nervous system because there are limited 
potential applications in the peripheral nervous system. Classifications of 
neuroenhancement may be developed according to two distinct categories: 1. the cognitive 
functions that are to be improved as well as the intentions and aims that underlie the use 
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and 2. the methods or routes that are employed. The different methods may result in 
permanent or temporary enhancement. 
Categories of neuroenhancement according to cognitive functions 
1. Sensory perception 
2. Motor action 
3. Communication 
4. Mood and emotions 
5. Cognition, narrowly conceived (e.g. attention, memory, decision-making) 
6. Social and moral behavior 
 
Fig. 3. Categories of neuroenhancement according to cognitive functions. 
This classification by cognitive roles and intentions covers all major functions that the 
central nervous system usually exercises. One overarching aim is to improve the interaction 
between the subject and the environment: A human needs to communicate effectively with 
her surroundings; both sensory uptake and motor output help this purpose. The other 
central aim is to expand the overall behavioral repertoire. This allows the person to act more 
freely and gives her more options to choose from – cognitively, socially, and morally. 
Neuroenhancement regarding sensory perception may mean to improve the functioning of the 
human senses or to potentially acquire new types of perception. For example, visual and 
auditory senses could be enhanced to include new wavelengths and frequencies outside the 
usual visible and audible spectrum. Regarding olfaction, humans may imitate dogs; as with 
all types of enhancement, however, it needs to be seen why they would want to procure this 
particular ability. – Motor neuroenhancement could lead to more efficient steering of technical 
devices. This type of use is largely futuristic; nevertheless, medical reports on tetraplegia 
(Hochberg et al., 2006) demonstrate that brain-machine interfaces can be utilized as 
therapies in order to expand the motor skills of severely compromised, wheelchair-bound 
patients. – Communication, enhanced by neurotechnology, appears as a promise with a high 
commercial potential. After all, recent years have seen a rise in communication technology, 
both towards large social networks and in favor of brief messages of an informational or 
emotional nature. Both trends could potentially continue with neuroenhancement. 
Emotions and mood are typically improved for therapeutic purposes in depressive patients. 
The slogan “Feeling ‘better than well’” (Hall, 2004) seems to suggest that people who 
consider their emotions as normal may feel even happier, more euphoric, or generally 
enhanced when they take antidepressants. – Cognitive functions in the narrow sense, such as 
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attention and memory, may become better through neuroenhancement as well. Some 
pharmaceutical drugs developed for medical purposes do improve concentration, at least 
temporarily  (Repantis et al., 2010). Medication that reduces the need for sleep also belongs 
to this general category. So-called “memory chips” are still very much a matter of 
speculation: These devices would store information outside of the brain, and they would 
allow access to deposit and retrieve these data (Groß, 2009b). – Social neuroscience aims at 
elucidating the determinants of living in groups and cultures. Eventually, the scientific 
results could be translated into opening up options for favorable social and moral behavior. 
A further classification of neuroenhancement relies on the methods that proponents pursue 
to achieve the goal. 
 
Fig. 4. Categories of neuroenhancement according to the methods employed. 
Categories of neuroenhancement according to the methods employed 
1. Pharmacology 
2. Interventions (surgical or minimally invasive) 
3. Non-invasive, external technology 
4. Invasive, internal technology 
In the following, the focus will be on pharmacological measures and implanted technology. 
4. Pharmacological and technological neuroenhancement 
Pharmacological neuroenhancement is known under different names, such as “cosmetic 
neurology” and “brain doping”. These latter terms clearly reflect the enhancement character 
of the endeavor. The medications used belong to a variety of medical classes, including 
pharmaceutical drugs used against depression (e.g. fluoxetine), dementia (e.g. donepezil), 
attention-deficit hyperactivity disorder (e.g. methylphenidate), and narcolepsy and sleeping 
disorders (e.g. modafinil) (Groß, 2009a). 
Neuroenhancing medication, therefore, is already a reality to a degree – as evidenced by the 
prevalence for the use of methylphenidate, modafinil, and antidepressants for this purpose 
particularly in the United States of America (Greely et al., 2008). The drugs are used in 
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schools, at universities, and at work for similar purposes: to improve objective performance 
parameters and to boost self-esteem. 
Interventions for neuroenhancement may be performed by microsurgery; however, these 
techniques do not yet exist. Non-invasive, external technology comprises brain stimulation 
techniques, such as transcranial magnetic stimulation (TMS) and transcranial direct current 
stimulation (tDCS). Although these methods possess potential to enhance brain function, 
they have not been developed to a degree to allow a reliable use for enhancement at the 
present time. 
The technological advancements that support neuroenhancement are largely futuristic. As 
discussed above, they can be categorized into attempts to improve sensory, motor, 
communicative, emotional, cognitive, and social functions. The technological products that 
are already available suggest that some enhancement strategies may be successful more 
readily than others. In particular, the following applications come to mind: supersensory 
perception, prosthesis steering, and more efficient communication. 
 
Fig. 5. Pursuits in technological neuroenhancement that are currently in development. 
Supersensory perception is already on the horizon, given the medical treatments of retinal, 
cochlear, and auditory brainstem implants (Groß, 2007a). Both humans (Hochberg et al., 
2006) and non-human primates (Velliste et al., 2008) have been capable of using brain-
machine interfaces to steer prosthesis. Brain signals can be analyzed for motor-independent 
communication (Monti et al., 2010). 
Emotions and mood may be changed by internal devices as well. In curative medicine, deep 
brain stimulation is an accepted treatment for Parkinson’s disease and essential tremor as 
well as other diseases (Deep-Brain Stimulation for Parkinson’s Disease Study Group, 2001). 
Deep brain stimulation is administered through electrodes that are implanted in deep 
regions of the brain, such as basal ganglia. Its effects include neurological and psychological 
ones, such as both positive and negative influences as well as side effects on extrapyramidal 
motor functions and emotional activation, which oftentimes manifests as euphoria and 
mania (Müller & Christen, 2011). Accordingly, a mild mode of stimulation might improve 
mood without other detrimental side effects. At this time, however, a wide-spread use of 
rather large, invasive electrodes is not conceivable for enhancement purposes. Regarding 
cognitive functions, memory chips have been discussed, but continue to remain elusive for 
now. Social and moral behavior is so complex and adaptable that it is currently unclear how to 
specifically enhance it, outside of general effects on emotional and cognitive states. 
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Neurotechnology has already been demonstrated to exhibit rather upsetting effects in some 
cases. In rats, a selective microstimulation technology for select brain areas has been used to 
coerce the animals into following certain paths that they would otherwise have shied away 
from (Talwar et al., 2006). Such applications lead to criticism against brain interventions per se. 
5. Principles in medical ethics 
Neuroenhancement can be assessed according to standard approaches in medical ethics, e.g. 
principlism, a strong contemporary attitude in medical ethics. It takes into consideration 
four principles, which draw widespread approval even from divergent ideological 
positions, namely autonomy, beneficence, non-maleficence, and justice (Beauchamp & 
Childress, 2009). These four tenets of the principlism approach in medical ethics appear to 
be very well applicable to emerging neurotechnology (Brukamp, 2010). 
The individual patient exercises his right to autonomy. Beneficence and non-maleficence are 
insofar related as they both stem from the perspective of an external, caring entity that seeks 
to minimize harm and maximize benefit to the individual. Justice is oftentimes applied from 
a standpoint above the individual, from a level of society, where all goods are supposed to 
be distributed according to just principles. 
 
Fig. 6. The four principles in the principlism approach within medical ethics. 
The principle of autonomy suggests enabling patients to exercise independence in their 
decision-making. They have to give their informed consent to any medical measure: First, 
patients are supposed to receive information about their conditions and treatment options, 
and this information needs to be tailored to their level of understanding. Second, they are to 
weigh the possibilities themselves and decide about the course of action that suits them best. 
Beneficence in the medical realm means to look out for and foster the benefit of patients or 
subjects. It may encompass supporting the development of devices to aid humans and 
acquiring evidence for their efficiency. Obviously, beneficence implies that technology, 
which helps humans, is backed in a number of ways, be it concerning research, 
development, production, accessibility, and distribution. Medical devices also need to be 
tested for efficiency according to the approved standards of evidence-based medicine 
(Sackett et al., 1996). Also, therapies are becoming more and more personalized, a trend that 
will likely grow in the future. This way, the therapy and enhancement strategies best suited 
for patients and subjects can be chosen out of a whole array of possibilities. 
Non-maleficence, as a principle in medical ethics, asks for a relative absence of negative side 
effects in relationship to the expected benefits. For example, a treatment with fewer side 
effects is preferable to one with more when both have the same efficacy. The traditional gold 
standard is an important guideline for comparison. The side effects need to be assessed in 
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relation to the benefits: Patients may prefer therapies that improve survival with more 
extensive side effects to those that only work on symptoms with less side effects. 
Distributive justice means that there is a kind of justified distribution of goods in society. 
This principle requires competent applications to specific situations. Theories of justice are 
wide, varied, and heterogeneous, and it therefore defies a brief, comprehensive discussion. 
Enhancement partially transcends medicine and is therefore subject to a distinct assessment. 
Nevertheless, enhancement falls under the extended realm of medical ethics so that the 
principlism approach still applies: 
First, neuroenhancement concerns the human being as a biological entity. It alters the 
physiological functions to achieve something unknown and unprecedented. Therefore, those 
principles from medical ethics apply that are relevant for the human as a biological entity. 
Second, the experts, who assist in the transformation, are the same in medical treatment and 
medical enhancement: For example, physicians’ expertise is needed to safely develop and 
apply new medications, interventions, and technologies. Since enhancement falls under the 
responsibility of medical providers, the normative principles from medical law and medical 
ethics apply by extension. 
Accordingly, applying the four principles from medical ethics yields the following 
perspectives and arguments, among others (Brukamp, 2010): 
Beneficence and non-maleficence may help to decide between different categories of 
neuroenhancement, namely pharmacological and technological ones. These strategies have 
diverse side effect profiles. Local treatments, instead of pharmacological ones, may 
sometimes meanless systemic side effects for the body. Conversely, pharmacological 
treatments can better be titrated, and increasing knowledge in cell and molecular biology 
might enable greater insights into mechanisms and eventually more specific treatments with 
medication. The number of options makes it possible to personalize the enhancement to 
individual needs. As a general rule, non-invasive measures are preferable to invasive ones 
because of a more moderate side effect profile. 
The steering of technological aids by neural signals, as one example of a potential future 
application in both neuromedicine and neuroenhancement, requires the acquisition of large 
amounts of digital data. According to the value of privacy, backed by the principles of 
autonomy, beneficence, and non-maleficence, such data should be utilized only for the 
benefit of the patients with their informed consent. Confidentiality in this context extends 
not only to the medical personnel, but to all people who come into contact with the data. 
This tenet becomes more difficult to be reinforced outside the medical field proper: 
Confidentiality has a tradition in professional contexts such as medicine, psychology, law, 
and theology, but its implications are less well known to other fields and the general public. 
The principle of justice entails that financial, time, personnel, and other resources in the health 
care system should not be diverted away from those who deserve them most. Therapies were 
developed to help the sick, disabled, and disadvantaged. Therefore, it would be wrong to 
strain the infrastructure and the resources of the medical system with the desires of too 
many clients who ask for enhancements. 
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6. Ethical assessment of neuroenhancement 
Applying the prominent four principles (Beauchamp & Childress, 2009) is one approach of 
addressing problems in medical ethics. Nevertheless, pro and con arguments may 
alternatively and more conveniently be grouped according to central topics, which seem to 
be defining features for the field in question. Accordingly, the current problems of 
pharmacological neuroenhancement, which extend, in part, to all types of potential future 
neuroenhancement, can be discussed along the issues of medical risk, lack of evidence, 
human nature, and justice. 
 
Fig. 7. For an overall assessment of neuroenhancement, there should be, among others, a 
consideration of medical risk, medical evidence, human nature, and distributive justice. The 
former two still belong to the narrower realm of responsibility for the field of medicine, 
whereas the arguments regarding the latter are derived from philosophical theory. 
Pharmacological neuroenhancers carry several medical risks with them (Banjo et al., 2010): 
They have side effects, there is a risk of addiction, and they may lose efficacy over time so 
that higher doses or drug combinations lead to even more risks. In addition, the medications 
may result in a wrongful subjective overestimation of one’s abilities, e.g. regarding attention 
and insomnia while driving in traffic, which can endanger oneself and others. In most cases, 
the long-term effects in the healthy population have simply not been studied and are 
unknown. 
The scientific and medical evidence that pharmacological neuroenhancers reliably work as 
expected is scarce. Reviews of the available data show that methylphenidate and modafinil can 
be said to exhibit some desired effects on healthy people, but may also lead to dangerous 
overconfidence in one’s possibilities (Repantis et al., 2010). Importantly, the end points for 
potential studies that test neuroenhancers have not been adequately defined: Which ones 
would be truly deserving and valid end points? They should extend beyond short-term effects 
and be compatible with other goals that humans have in life. Once these end points are 
defined, high-quality studies then need to prove the efficacy of the neuroenhancers to achieve 
them, according to the standards of evidence-based medicine (Sackett et al., 1996). 
Humans normally value truth, authenticity, and personal identity (The President’s Council 
on Bioethics, 2003). Some opponents to neuroenhancement regard artificial means for 
enhancements as (self-)deception and as a threat to human nature. Nevertheless, humans 
have always tried to use tools and to embellish themselves by socially accepted external 
means – this seems to be a feature of human nature itself. Consequently, the reference to 
human nature is not one that helps to decide easily between appropriate and inappropriate 
www.intechopen.com
 
Contemporary Issues in Bioethics 
 
48
means of self-improvement; rather, it needs to be applied aptly to different contexts (Groß, 
2007a, 2007b). 
Supporters of neuroenhancement frequently argue that behavioral modifications have 
always been employed to achieve the same goals that neuroenhancement serves  (Greely et 
al., 2008) – for example, measures like classic learning and psychotherapy have widely been 
accepted as valid means. These proponents do not admit that a clear-cut boundary exists 
between the traditional methods for self-improvement and the novel prospects of 
neuroenhancement. Nevertheless, such distinctive features of the latter are indeed present 
and discernible: Medical risks are higher, due to more direct alterations in the brain by 
medication use or invasive measures; procedures deemed artificial can result in feelings of 
external determination and self-alienation; effects may suddenly cease secondary to a lack of 
access to medication or because of technological malfunction, which may be immediate and 
unforeseeable phenomena. 
Considerations from justice concern access and coercion. While neuroenhancement may 
serve the purpose of creating a level playing field for naturally disadvantaged people, 
performance gaps between groups may widen because of unequal access to the 
supposedly enhancing medication. Moreover, vulnerable groups, such as children, could 
experience peer pressure in favor of drug use. Due to their vulnerability, for example 
because of ongoing brain development, the negative side effects may actually become 
more extensive. 
In summary, a number of arguments caution against the use of neuroenhancement, in 
particular of the pharmacological variety in use today. Medical arguments refer to risks 
from medication side effects and from overestimations of one’s own abilities, which may 
become dangerous for oneself and others. Besides, the current evidence for the efficacy of 
neuroenhancers, aside from short-term effects of some, is thin. While human beings possess 
a desire for enhancements, not all types are considered compatible with the development 
and protection of human nature and identity. Enhancement in general may divert resources 
away from the classic medical system, constituting a challenge to the principle of 
distributive justice (Racine & Forlini, 2009). Sociological arguments claim that equal access 
to enhancement routes cannot be guaranteed, and coercion may result in ill effects, 
particularly in vulnerable groups who cannot decide for themselves, like children. 
7. Conclusion 
In conclusion, neuroenhancement poses problems due to its nature as a novel enhancement 
method and because it concerns an organ that mediates human identity. While it cannot be 
ruled out that acceptable and affordable means may be developed in the future, the long-
term benefits cannot easily be foreseen at this time, both on the individual level and from 
the perspective of society as a whole. Therefore, the best advice is a cautious approach, and 
the current situation warrants an overall precautionary stance towards neuroenhancement. 
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